Interleaved deep brain stimulation for dyskinesia management in Parkinson's disease

Camila C. Aquino; Gordon Duffley; David M. Hedges; Johannes Vorwerk; Paul A. House; Henrique B. Ferraz; John D. Rolston; Christopher R. Butson; Lauren E. Schrock

doi:10.1002/mds.27839

Interleaved deep brain stimulation for dyskinesia management in Parkinson's disease

Camila C. Aquino, Gordon Duffley, David M. Hedges, Johannes Vorwerk, Paul A. House, Henrique B. Ferraz, John D. Rolston, Christopher R. Butson, Lauren E. Schrock

Neurology

Research output: Contribution to journal › Article › peer-review

18 Scopus citations

Abstract

Background: In patients with Parkinson's disease, stimulation above the subthalamic nucleus (STN) may engage the pallidofugal fibers and directly suppress dyskinesia. Objectives: The objective of this study was to evaluate the effect of interleaving stimulation through a dorsal deep brain stimulation contact above the STN in a cohort of PD patients and to define the volume of tissue activated with antidyskinesia effects. Methods: We analyzed the Core Assessment Program for Surgical Interventional Therapies dyskinesia scale, Unified Parkinson's Disease Rating Scale parts III and IV, and other endpoints in 20 patients with interleaving stimulation for management of dyskinesia. Individual models of volume of tissue activated and heat maps were used to identify stimulation sites with antidyskinesia effects. Results: The Core Assessment Program for Surgical Interventional Therapies dyskinesia score in the on medication phase improved 70.9 ± 20.6% from baseline with noninterleaved settings (P < 0.003). With interleaved settings, dyskinesia improved 82.0 ± 27.3% from baseline (P < 0.001) and 61.6 ± 39.3% from the noninterleaved phase (P = 0.006). The heat map showed a concentration of volume of tissue activated dorsally to the STN during the interleaved setting with an antidyskinesia effect. Conclusion: Interleaved deep brain stimulation using the dorsal contacts can directly suppress dyskinesia, probably because of the involvement of the pallidofugal tract, allowing more conservative medication reduction.

Original language	English (US)
Pages (from-to)	1722-1727
Number of pages	6
Journal	Movement Disorders
Volume	34
Issue number	11
DOIs	https://doi.org/10.1002/mds.27839
State	Published - Nov 1 2019

Bibliographical note

Funding Information:
We acknowledge the essential contribution of Desiree Davis, RN, Meghan Zorn, PA, Perla Thulin, MD, and Paolo Moretti, MD, for providing excellent care for patients with Parkinson's disease at the University of Utah. We also acknowledge the work of James Ballard, PT, DPT, and Kevin Duff, PhD, for conducting motor evaluation and neuropsychological assessments of all deep brain stimulation candidates at the University of Utah. We thank Holly Cushing, PA, for the contribution to data collection and our patients for their willingness to collaborate in the research.

Publisher Copyright:
© 2019 International Parkinson and Movement Disorder Society

Keywords

Parkinson's disease
deep brain stimulation
dyskinesia
interleaving
volume of tissue activated

Access

10.1002/mds.27839

OpenUrl availability

Full text

Cite this

@article{2c9cae9a5c7b4db487e681fd7bf68235,

title = "Interleaved deep brain stimulation for dyskinesia management in Parkinson's disease",

abstract = "Background: In patients with Parkinson's disease, stimulation above the subthalamic nucleus (STN) may engage the pallidofugal fibers and directly suppress dyskinesia. Objectives: The objective of this study was to evaluate the effect of interleaving stimulation through a dorsal deep brain stimulation contact above the STN in a cohort of PD patients and to define the volume of tissue activated with antidyskinesia effects. Methods: We analyzed the Core Assessment Program for Surgical Interventional Therapies dyskinesia scale, Unified Parkinson's Disease Rating Scale parts III and IV, and other endpoints in 20 patients with interleaving stimulation for management of dyskinesia. Individual models of volume of tissue activated and heat maps were used to identify stimulation sites with antidyskinesia effects. Results: The Core Assessment Program for Surgical Interventional Therapies dyskinesia score in the on medication phase improved 70.9 ± 20.6% from baseline with noninterleaved settings (P < 0.003). With interleaved settings, dyskinesia improved 82.0 ± 27.3% from baseline (P < 0.001) and 61.6 ± 39.3% from the noninterleaved phase (P = 0.006). The heat map showed a concentration of volume of tissue activated dorsally to the STN during the interleaved setting with an antidyskinesia effect. Conclusion: Interleaved deep brain stimulation using the dorsal contacts can directly suppress dyskinesia, probably because of the involvement of the pallidofugal tract, allowing more conservative medication reduction.",

keywords = "Parkinson's disease, deep brain stimulation, dyskinesia, interleaving, volume of tissue activated",

author = "Aquino, {Camila C.} and Gordon Duffley and Hedges, {David M.} and Johannes Vorwerk and House, {Paul A.} and Ferraz, {Henrique B.} and Rolston, {John D.} and Butson, {Christopher R.} and Schrock, {Lauren E.}",

note = "Funding Information: We acknowledge the essential contribution of Desiree Davis, RN, Meghan Zorn, PA, Perla Thulin, MD, and Paolo Moretti, MD, for providing excellent care for patients with Parkinson's disease at the University of Utah. We also acknowledge the work of James Ballard, PT, DPT, and Kevin Duff, PhD, for conducting motor evaluation and neuropsychological assessments of all deep brain stimulation candidates at the University of Utah. We thank Holly Cushing, PA, for the contribution to data collection and our patients for their willingness to collaborate in the research. Publisher Copyright: {\textcopyright} 2019 International Parkinson and Movement Disorder Society",

year = "2019",

month = nov,

day = "1",

doi = "10.1002/mds.27839",

language = "English (US)",

volume = "34",

pages = "1722--1727",

journal = "Movement Disorders",

issn = "0885-3185",

publisher = "John Wiley and Sons Inc.",

number = "11",

}

TY - JOUR

T1 - Interleaved deep brain stimulation for dyskinesia management in Parkinson's disease

AU - Aquino, Camila C.

AU - Duffley, Gordon

AU - Hedges, David M.

AU - Vorwerk, Johannes

AU - House, Paul A.

AU - Ferraz, Henrique B.

AU - Rolston, John D.

AU - Butson, Christopher R.

AU - Schrock, Lauren E.

N1 - Funding Information: We acknowledge the essential contribution of Desiree Davis, RN, Meghan Zorn, PA, Perla Thulin, MD, and Paolo Moretti, MD, for providing excellent care for patients with Parkinson's disease at the University of Utah. We also acknowledge the work of James Ballard, PT, DPT, and Kevin Duff, PhD, for conducting motor evaluation and neuropsychological assessments of all deep brain stimulation candidates at the University of Utah. We thank Holly Cushing, PA, for the contribution to data collection and our patients for their willingness to collaborate in the research. Publisher Copyright: © 2019 International Parkinson and Movement Disorder Society

PY - 2019/11/1

Y1 - 2019/11/1

N2 - Background: In patients with Parkinson's disease, stimulation above the subthalamic nucleus (STN) may engage the pallidofugal fibers and directly suppress dyskinesia. Objectives: The objective of this study was to evaluate the effect of interleaving stimulation through a dorsal deep brain stimulation contact above the STN in a cohort of PD patients and to define the volume of tissue activated with antidyskinesia effects. Methods: We analyzed the Core Assessment Program for Surgical Interventional Therapies dyskinesia scale, Unified Parkinson's Disease Rating Scale parts III and IV, and other endpoints in 20 patients with interleaving stimulation for management of dyskinesia. Individual models of volume of tissue activated and heat maps were used to identify stimulation sites with antidyskinesia effects. Results: The Core Assessment Program for Surgical Interventional Therapies dyskinesia score in the on medication phase improved 70.9 ± 20.6% from baseline with noninterleaved settings (P < 0.003). With interleaved settings, dyskinesia improved 82.0 ± 27.3% from baseline (P < 0.001) and 61.6 ± 39.3% from the noninterleaved phase (P = 0.006). The heat map showed a concentration of volume of tissue activated dorsally to the STN during the interleaved setting with an antidyskinesia effect. Conclusion: Interleaved deep brain stimulation using the dorsal contacts can directly suppress dyskinesia, probably because of the involvement of the pallidofugal tract, allowing more conservative medication reduction.

AB - Background: In patients with Parkinson's disease, stimulation above the subthalamic nucleus (STN) may engage the pallidofugal fibers and directly suppress dyskinesia. Objectives: The objective of this study was to evaluate the effect of interleaving stimulation through a dorsal deep brain stimulation contact above the STN in a cohort of PD patients and to define the volume of tissue activated with antidyskinesia effects. Methods: We analyzed the Core Assessment Program for Surgical Interventional Therapies dyskinesia scale, Unified Parkinson's Disease Rating Scale parts III and IV, and other endpoints in 20 patients with interleaving stimulation for management of dyskinesia. Individual models of volume of tissue activated and heat maps were used to identify stimulation sites with antidyskinesia effects. Results: The Core Assessment Program for Surgical Interventional Therapies dyskinesia score in the on medication phase improved 70.9 ± 20.6% from baseline with noninterleaved settings (P < 0.003). With interleaved settings, dyskinesia improved 82.0 ± 27.3% from baseline (P < 0.001) and 61.6 ± 39.3% from the noninterleaved phase (P = 0.006). The heat map showed a concentration of volume of tissue activated dorsally to the STN during the interleaved setting with an antidyskinesia effect. Conclusion: Interleaved deep brain stimulation using the dorsal contacts can directly suppress dyskinesia, probably because of the involvement of the pallidofugal tract, allowing more conservative medication reduction.

KW - Parkinson's disease

KW - deep brain stimulation

KW - dyskinesia

KW - interleaving

KW - volume of tissue activated

UR - http://www.scopus.com/inward/record.url?scp=85072009641&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072009641&partnerID=8YFLogxK

U2 - 10.1002/mds.27839

DO - 10.1002/mds.27839

M3 - Article

C2 - 31483534

AN - SCOPUS:85072009641

SN - 0885-3185

VL - 34

SP - 1722

EP - 1727

JO - Movement Disorders

JF - Movement Disorders

IS - 11

ER -

Interleaved deep brain stimulation for dyskinesia management in Parkinson's disease

Abstract

Bibliographical note

Keywords

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this